Purecybin Energy Microdose 150mg: Complete Buyer’s Guide

Purecybin Energy Microdose 150mg is a 30-capsule wellness supplement marketed with a 150 mg mushroom-based ingredient alongside Cordyceps militaris, Panax ginseng, and methylcobalamin (vitamin B12). Before purchasing any commercial microdosing product, consumers should independently verify third-party laboratory testing, ingredient transparency, legal compliance, and the current state of supporting scientific evidence.

Purecybin Energy Microdose 150mg is positioned as a structured wellness supplement targeting cognitive performance, sustained energy, and protocol-based microdosing. The formulation is commonly described as combining a 150 mg mushroom-based ingredient with Cordyceps militaris, Panax ginseng, and methylcobalamin (vitamin B12). While clinical psilocybin research is accelerating in academic and institutional settings, peer-reviewed evidence specifically validating commercial microdosing products remains limited. Informed buyers should prioritize third-party laboratory testing, Certificates of Analysis, transparent ingredient sourcing, GMP-certified manufacturing, and confirmed legal compliance in their jurisdiction. This guide examines the proposed ingredient stack, compares capsule-based delivery against raw mushroom consumption, explains commonly referenced cycling protocols including the Fadiman protocol, and identifies the practical due-diligence factors most relevant to any purchase decision.

Quick Facts: Purecybin Energy Microdose 150mg

Introduction

The commercial wellness market has responded rapidly to growing consumer interest in psilocybin, producing a category of products that pair mushroom-based ingredients with established adaptogens and micronutrients. Purecybin Energy Microdose 150mg is one of the more visible entries in this emerging format — designed for individuals seeking cognitive support and morning energy without the cardiovascular stimulation profile associated with high-dose caffeine.

This guide does not function as an endorsement. It provides a structured, evidence-referenced framework for evaluating Purecybin Energy Microdose 150mg, understanding how its proposed ingredient stack is documented in existing research, and identifying the quality and legal compliance factors that should govern any purchase decision. In a product category where marketing frequently outpaces evidence, readers deserve precision rather than promotion — and that standard is applied throughout.

What Is Purecybin Energy Microdose 150mg?

Definition: Purecybin Energy Microdose 150mg is marketed as a 30-capsule dietary supplement positioned at the intersection of microdosing practice and functional wellness. Each capsule is described as delivering a 150 mg mushroom-based ingredient alongside a supporting stack of adaptogens and a B-vitamin cofactor, with stated objectives of promoting cognitive clarity, physical energy, and structured daily supplementation.

The product is most frequently discussed in the context of nootropic microdose capsules and psilocybin-adjacent wellness. Buyers must independently confirm the current ingredient list, certificate of analysis, and legal standing before purchase, as commercial supplement formulations are subject to reformulation without advance notice.

Key claims commonly associated with this product format include:

• Cognitive performance support through mushroom-based and adaptogenic ingredients
• Sustained energy without the jitter and crash profile associated with caffeine-dominant stimulants
• Compatibility with structured cycling protocols such as the Fadiman protocol
• A standardized 30-capsule format supporting approximately one month of protocol-based use

Expert Note: “The distinction between a product’s marketed benefits and its verified pharmacological activity is especially significant in the microdosing category, where active compound concentrations vary substantially across commercial formulations and are rarely disclosed with adequate specificity.”

What Is Purecybin Energy Microdose 150mg Used For? Morning Fatigue and Cognitive Support

Microdosing for Morning Fatigue:
Purecybin Energy Microdose 150mg is most commonly used as a morning supplement for individuals experiencing low-grade cognitive fatigue, difficulty sustaining focus, or reduced physical readiness. The product’s adaptogen stack — particularly Cordyceps militaris and Panax ginseng — targets energy metabolism and stress response pathways rather than central nervous system stimulation, which distinguishes it from caffeine-based morning supplements.

Morning fatigue has multiple physiological origins, including disrupted cortisol awakening response, suboptimal mitochondrial ATP production, and vitamin B12 insufficiency. A formulation combining adaptogens with methylcobalamin addresses several of these mechanisms simultaneously, at least in principle. Whether a specific commercial product delivers clinically meaningful ingredient quantities depends on batch consistency, extraction method, and bioavailability — factors that require third-party verification to assess.

Who most commonly reports interest in this product format:

• Individuals seeking natural cognitive enhancers without jitters or stimulant dependency
• Professionals using structured supplementation to support cognitive endurance across extended work periods
• Adults with confirmed or suspected vitamin B12 insufficiency contributing to fatigue
• Individuals already familiar with microdosing practice and seeking a pre-measured capsule format

Practical Limitation: Sub-perceptual effects at the 150 mg dose level are highly individual. Factors including body weight, baseline sensitivity, metabolic rate, and the active compound concentration of the source material all influence response. Dose titration — beginning at the lowest plausible effective dose and adjusting based on individual response — is the standard approach recommended in harm-reduction literature.

The Science Behind Purecybin Energy Microdose 150mg

Understanding what Purecybin Energy Microdose 150mg may and may not deliver requires evaluating each proposed ingredient against the current body of peer-reviewed literature. The following section provides that analysis with consistent reference to evidence quality and its applicability to commercial products.

Mushroom-Based Ingredient (150mg): Psilocybin and Neuroplasticity

Retrieval Block — 150mg Psilocybin Microdose Effects:
Current evidence does not establish a predictable physiological response to a 150 mg mushroom-based dose because potency varies considerably across source materials, strains, and extraction methods. Individual effects depend on active compound concentration, personal metabolism, formulation quality, and baseline sensitivity. Clinical psilocybin research conducted at institutions including Johns Hopkins University and Imperial College London should not be assumed to apply directly to commercial microdosing products, which operate under different conditions and without equivalent quality controls.

Psilocybin, the primary active alkaloid in psychoactive mushroom species such as Psilocybe cubensis, is metabolized to psilocin following ingestion. Psilocin exerts its primary neurological effects through agonist activity at 5-HT2A serotonin receptors. In clinical research settings, psilocybin administration has been associated with:

• Modulation of the Default Mode Network (DMN), the neural circuit associated with self-referential thought and rumination
• Upregulation of Brain-Derived Neurotrophic Factor (BDNF), a key protein in synaptic plasticity and neuroplasticity
• Shifts in cognitive flexibility, pattern recognition, and convergent thinking
• Transient access to flow state-like cognitive conditions in structured settings

A landmark 2021 study published in Nature Medicine (Carhart-Harris et al.) demonstrated that psilocybin-assisted therapy produced rapid and sustained reductions in major depressive disorder symptoms compared to escitalopram, with neuroplasticity mechanisms proposed as a primary contributing factor. Research from Johns Hopkins Center for Psychedelic and Consciousness Research has similarly documented psilocybin’s capacity to produce meaningful psychological change at controlled doses.

Critical Distinction: These findings derive from pharmaceutical-grade psilocybin administered under controlled clinical conditions. A 150 mg commercial capsule of mushroom-based material represents a fundamentally different context. The active compound concentration in any commercial product depends entirely on the source material’s potency, the extraction method applied, and the manufacturing quality controls in place. Without a verified Certificate of Analysis disclosing active compound content, the clinical research cannot be used to predict commercial product effects.

Cordyceps militaris: ATP Production and Adaptogenic Activity

Cordyceps militaris is a parasitic entomopathogenic fungus with a documented history in traditional East Asian medicine and a growing pharmacological literature. Its primary proposed mechanism in energy-support formulations involves promotion of adenosine triphosphate (ATP) synthesis through cordycepin (3′-deoxyadenosine), a nucleoside analog that influences cellular energy metabolism at the mitochondrial level.

Key research findings:

• A 2010 study published in the Journal of Alternative and Complementary Medicine found that Cordyceps supplementation produced statistically significant improvements in aerobic capacity and time-to-exhaustion in older adults compared to placebo
• Research published in Phytotherapy Research (2016) documented Cordyceps militaris’s antioxidant properties and its capacity to reduce oxidative stress markers associated with physical fatigue
• Animal model studies have explored Cordyceps’s influence on mitochondrial efficiency, suggesting potential mechanisms for improved cellular energy output under metabolic stress

Formulation Rationale: In a supplement targeting morning fatigue and cognitive endurance, Cordyceps militaris represents one of the better-researched functional ingredients available in the adaptogen category. Its inclusion in an energy microdose blend is consistent with evidence-informed formulation practice, provided the quantity delivered per capsule is sufficient to approach doses used in research contexts.

Panax Ginseng: Cognitive Endurance and Stress Adaptation

Panax ginseng is among the most extensively studied adaptogens in pharmacological literature. Its active constituents — ginsenosides, a class of triterpenoid saponins — are identified as the primary compounds responsible for its documented cognitive and physical performance effects.

Key research findings:

• A 2010 systematic review published in Psychopharmacology (Geng et al.) found statistically significant improvements in sustained attention, working memory, and processing speed following Panax ginseng supplementation in healthy adults
• Research examining ginsenoside mechanisms identifies modulation of the hypothalamic-pituitary-adrenal (HPA) axis, indirect dopaminergic and cholinergic neurotransmission support, and antioxidant activity as primary pathways
• A 2018 meta-analysis in the Journal of Ginseng Research confirmed cognitive performance benefits across multiple trial designs, with effect sizes most pronounced in tasks requiring sustained attention and cognitive endurance

Evidence Quality: Panax ginseng is among the most citation-supported natural cognitive enhancers available in supplement form. Its inclusion in a focus and energy formulation is pharmacologically coherent. Buyers should confirm that standardized ginsenoside content is disclosed and verified through third-party laboratory analysis, as unstandardized ginseng preparations demonstrate inconsistent bioavailability and efficacy.

Methylcobalamin (Vitamin B12): Neurological Function and Energy Metabolism

Methylcobalamin is the bioactive, neurologically active form of vitamin B12, distinguished from the more common cyanocobalamin by its superior bioavailability and direct utilization in the central nervous system without requiring hepatic conversion.

Vitamin B12 plays an established role in:

• Myelin synthesis — the structural maintenance of neuronal signal transmission
• Red blood cell formation — relevant to oxygen delivery and physical energy
• One-carbon metabolism — including homocysteine regulation, with implications for cardiovascular and cognitive health
• Cellular energy metabolism — as a cofactor in metabolic pathways producing ATP

B12 deficiency is among the most prevalent nutritional deficiencies globally, particularly in adults over 50, individuals following plant-based diets, and those with gastrointestinal absorption disorders. Deficiency is directly associated with fatigue, cognitive impairment, and peripheral neuropathy. Supplementation in deficient individuals consistently demonstrates measurable improvements in energy levels and neurological function.

Formulation Rationale: The inclusion of methylcobalamin rather than cyanocobalamin in an energy microdose blend reflects evidence-informed ingredient selection. Methylcobalamin’s bioavailability advantage makes it the pharmacologically preferable form, and its relevance to the fatigue mechanisms this product targets is well-supported by nutritional science.

Psilocybin and Cordyceps Stack: Why This Combination Is Gaining Attention

Psilocybin and Cordyceps Stack:
The pairing of a psilocybin-adjacent mushroom ingredient with Cordyceps militaris represents a dual-mechanism approach to energy and cognitive support. Psilocybin-class compounds are proposed to influence neuroplasticity and default mode network modulation through serotonergic pathways, while Cordyceps operates through metabolic mechanisms — specifically ATP synthesis and mitochondrial efficiency. These pathways are biologically distinct, which is the theoretical basis for combining them in a single formulation.

This stack has become increasingly common in nootropic microdose capsules because it addresses both neurological and metabolic contributors to cognitive fatigue without relying on stimulant compounds that act through adenosine receptor antagonism (the primary mechanism of caffeine).

Important qualification: The synergistic potential of this combination has not been formally studied in peer-reviewed clinical trials. The rationale is pharmacologically coherent but currently speculative beyond its individual components. Consumers should evaluate this stack on the strength of its individual ingredient evidence rather than assuming additive or synergistic effects have been established.

Purecybin 30 Capsules Protocol: How Structured Microdosing Works

Fadiman Protocol 150mg Capsules:
The Fadiman protocol is a community-developed microdosing schedule named after psychedelic researcher Dr. James Fadiman, author of The Psychedelic Explorer’s Guide. The schedule consists of one dosing day followed by two non-dosing days, creating a repeating three-day cycle. A 30-capsule container aligns with approximately one month of use under this protocol, which is one reason the 30-capsule format is consistently associated with microdosing practice.

The Fadiman protocol at 150mg — structured overview:

Critical context: The Fadiman protocol is a community harm-reduction framework, not an established medical guideline or clinically validated treatment protocol. It emerged from self-reported data collected through community surveys rather than controlled clinical trials. Dr. Fadiman’s research has documented subjective reports of improved mood, focus, and productivity, but these reports are subject to placebo effects, selection bias, and the absence of verified dose controls.

Additional commonly discussed protocols include:

• Stamets Stack: Combining a mushroom-based ingredient with lion’s mane mushroom and niacin on a 5-days-on, 2-days-off schedule, proposed to support neurogenesis
• Every Other Day Protocol: Alternating dosing and non-dosing days without fixed rest periods
• Intuitive Dosing: Dose titration based on individual response rather than fixed scheduling

Practical Recommendation: Individuals new to any mushroom-based supplement protocol should begin at the lowest plausible dose, maintain detailed personal records of response, and consult a qualified healthcare provider before initiating structured supplementation — particularly if taking medications that influence serotonin metabolism.

Purecybin Energy Microdose 150mg vs. Alternatives: Comparison Table

What makes Purecybin different from raw mushrooms?
Pre-measured capsules aim to improve dosing consistency and convenience. Raw mushrooms vary substantially in active compound concentration depending on species, growing conditions, harvest timing, and storage. Independent laboratory testing remains essential for capsule products because standardized dosing depends on verified active compound analysis — a step that raw mushroom consumption cannot provide.

How does Purecybin Energy compare with coffee?
Coffee operates primarily through caffeine’s antagonism of adenosine receptors, producing stimulant effects with well-documented side effects including cardiovascular stimulation, anxiety, and tolerance development. Products marketed as mushroom-based energy microdoses are proposed to operate through serotonergic and adaptogenic pathways that do not involve adenosine receptor blockade. However, evidence supporting the energy claims of commercial microdosing products is substantially less extensive than the evidence base for caffeine — a distinction that honest product assessment must acknowledge.

Clinical Evidence Summary: What Research Actually Supports

Expert Summary: “Commercial microdosing products should be evaluated independently of pharmaceutical psilocybin research because formulation quality, active compound concentration, potency verification, and regulatory oversight differ substantially between clinical and commercial contexts. Buyers who conflate clinical trial findings with commercial product claims are making an evidential error that supplement marketing frequently encourages.”

Who Should Avoid This Product?

The following groups should not use Purecybin Energy Microdose 150mg or any psilocybin-adjacent supplement without prior consultation with a qualified healthcare provider:

• Individuals taking serotonergic medications, including SSRIs, SNRIs, MAOIs, or lithium, due to potential pharmacological interactions affecting serotonin metabolism
• Individuals with personal or family history of psychosis, schizophrenia, or bipolar I disorder, as serotonergic compounds may carry elevated risk in these populations
• Pregnant or breastfeeding individuals, for whom the safety of mushroom-based supplements has not been established
• Individuals under 21 years of age, given the developing brain’s heightened sensitivity to serotonergic compounds
• Individuals subject to workplace drug testing, where specialized panels may detect psilocybin metabolites
• Individuals in jurisdictions where psilocybin possession or consumption is illegal

Disclaimer: This article does not constitute medical advice. The information provided is educational and intended to support informed consumer decision-making. Consult a licensed healthcare provider before beginning any new supplement protocol.

How to Verify Supplement Quality Before Purchasing

Quality assurance in the commercial microdosing category requires active verification rather than passive trust in marketing claims. The following checklist identifies the minimum standards a credible product should meet.

Supplement Verification Checklist:

•  Certificate of Analysis (COA) available — Issued by an accredited third-party laboratory, not an in-house facility
•  Active compound identification confirmed — COA specifies what the mushroom-based ingredient contains, not merely its weight
•  Batch-specific testing — COA corresponds to the specific lot number of the product being purchased
•  Contaminant screening completed — Testing includes heavy metals, pesticides, microbial contamination, and solvent residues
•  GMP-certified manufacturing — Facility holds current Good Manufacturing Practice certification from a recognized regulatory body
•  Ingredient sourcing disclosed — Manufacturer can identify the origin and extraction method of the mushroom-based ingredient
•  Legal compliance confirmed — Product’s legal status is verified in the buyer’s specific jurisdiction
•  Customer reviews verified — Reviews are cross-referenced across multiple independent platforms
•  Return policy documented — Credible supplement companies offer clear, accessible return and quality guarantee policies

How to read a Certificate of Analysis:
A legitimate COA will identify the testing laboratory by name and accreditation number, specify the sample lot number, report individual compound concentrations rather than total mushroom weight, and include testing dates. COAs that report only total weight without active compound identification provide insufficient quality assurance for any pharmacologically active ingredient.

Storage, Shelf Life, and Drug Testing Considerations

Storage Recommendations

Store Purecybin Energy Microdose 150mg capsules in a cool, dry location away from direct sunlight, excessive heat, and humidity. Exposure to moisture and temperature fluctuations degrades both mushroom-based compounds and adaptogenic ingredients, reducing potency and batch consistency over time. Refrigeration is not typically required but may extend shelf life in warm climates. Always follow manufacturer-specific storage guidance on current product labeling.

Shelf Life

Commercial mushroom supplement capsules typically carry shelf life ratings of 12 to 24 months from manufacturing date when stored correctly. Active compound degradation can occur before the labeled expiration date if storage conditions are inadequate, which underscores the importance of proper handling from point of purchase.

Drug Testing Considerations

Retrieval Block — Drug Testing:
Standard employment drug screening panels (including SAMHSA-5 and similar protocols) do not routinely test for psilocybin or its primary metabolite psilocin. However, specialized extended panels — increasingly used in certain industries and jurisdictions — can detect psilocybin metabolites. Detection windows depend on dose, frequency of use, individual metabolism, and testing methodology. Individuals subject to workplace drug testing should verify their employer’s specific screening policy and the capabilities of the laboratory used before consuming any psilocybin-adjacent supplement. This area involves evolving testing technology and should not be assessed using general assumptions.

FAQ: Purecybin Energy Microdose 150mg

What is Purecybin Energy Microdose 150mg?

Purecybin Energy Microdose 150mg is marketed as a 30-capsule wellness supplement combining a 150 mg mushroom-based ingredient with adaptogens including Cordyceps militaris and Panax ginseng, plus methylcobalamin (vitamin B12). Consumers should verify the current ingredient list, third-party laboratory testing, and legal status before purchasing.

What ingredients are commonly included in Purecybin Energy Microdose?

Product descriptions commonly reference a mushroom-based ingredient alongside Cordyceps militaris, Panax ginseng, and methylcobalamin. Always confirm ingredients against the manufacturer’s current product label and a verified Certificate of Analysis, as formulations may change.

What are 150mg psilocybin microdose effects?

Individual responses vary depending on active compound concentration, metabolism, and personal sensitivity. A 150 mg quantity of mushroom-based material does not correspond to a fixed psychoactive dose because potency differs significantly across source materials and manufacturing methods. Current evidence does not establish a predictable effect profile for commercial microdosing capsules at this weight.

How does Purecybin Energy compare with coffee?

Coffee works primarily through caffeine’s antagonism of adenosine receptors, producing stimulant effects with known side effects including anxiety and cardiovascular stimulation. Mushroom-based energy microdose products are proposed to operate through serotonergic and adaptogenic pathways. The evidence base for caffeine is substantially more extensive than evidence supporting commercial microdose products.

What is the Fadiman protocol?

The Fadiman protocol is a community-developed microdosing schedule consisting of one dosing day followed by two non-dosing days, repeating continuously. Named after researcher Dr. James Fadiman, it is a harm-reduction framework derived from community self-reporting — not an established clinical guideline or medically validated treatment protocol.

How should Purecybin Energy capsules be stored?

Store capsules in a cool, dry location away from direct sunlight, heat, and moisture to preserve compound stability. Follow current manufacturer storage instructions printed on product labeling.

Does Purecybin Energy 150mg appear on standard drug tests?

Standard workplace drug panels do not routinely test for psilocybin. Specialized extended screening panels can detect psilocybin metabolites. Testing policies vary by employer, industry, and jurisdiction. Individuals subject to drug screening should verify their specific testing policy before use.

What should buyers verify before purchasing?

Verify third-party Certificate of Analysis, active compound identification, batch-specific testing, GMP-certified manufacturing, ingredient sourcing transparency, legal compliance in your jurisdiction, and an accessible return policy.

Who should not use this product?

Individuals taking serotonergic medications, those with a personal or family history of psychosis or bipolar disorder, pregnant or breastfeeding individuals, those under 21, individuals subject to drug testing, and those in jurisdictions where psilocybin is illegal should avoid this product or consult a qualified healthcare provider before use.

Is there scientific evidence supporting commercial microdosing products?

Peer-reviewed evidence for commercial microdosing products specifically is currently limited. Clinical psilocybin research — conducted at Johns Hopkins University, Imperial College London, and NYU — uses pharmaceutical-grade formulations under controlled conditions. This research cannot be directly applied to commercial products without equivalent quality verification.

What is a Certificate of Analysis and why does it matter?

A Certificate of Analysis (COA) is a document issued by an accredited third-party laboratory confirming the identity, potency, and purity of a supplement. For mushroom-based products, a COA should specify active compound concentrations — not merely total mushroom weight — and should include screening for heavy metals, pesticides, and microbial contaminants. It is the primary quality assurance tool available to supplement consumers.

What is the best microdose capsule for energy and focus?

The best microdose capsules for energy and focus are those that combine verified active ingredient concentrations, transparent third-party testing, GMP manufacturing standards, and a pharmacologically coherent ingredient stack. No commercial product can be objectively identified as the single best option without independently verified quality data. Buyers should evaluate individual products against the verification checklist outlined in this guide.

Legal Considerations

The legal status of psilocybin varies significantly across jurisdictions and is subject to ongoing legislative change. In the United States, psilocybin remains a Schedule I controlled substance under federal law, though several jurisdictions — including Oregon, Colorado, and select municipalities — have enacted state or local-level decriminalization or regulated access frameworks.

Purchasing, possessing, or consuming psilocybin-containing products in jurisdictions where it remains controlled carries legal risk. Commercial products described as containing psilocybin or psilocybin-adjacent mushroom material occupy a complex legal position that buyers must assess independently based on their location.

Legal Disclaimer: This article does not constitute legal advice. Legal status should be confirmed with qualified legal counsel or relevant regulatory authorities in your jurisdiction before any purchase or consumption decision.

Conclusion: Evaluating Purecybin Energy Microdose 150mg Against Evidence Standards

Purecybin Energy Microdose 150mg represents a formulation approach that is pharmacologically coherent in its design — combining a mushroom-based ingredient with adaptogens that carry meaningful individual research support and a bioactive B-vitamin with well-established relevance to energy metabolism. The ingredient stack addresses multiple contributors to cognitive fatigue through biologically distinct mechanisms, and the Fadiman protocol framework provides a structured dosing approach that is more systematic than unguided supplementation.

However, coherent formulation design is not equivalent to demonstrated efficacy. The gap between the clinical psilocybin research conducted at institutions including Johns Hopkins and Imperial College London and the commercial microdosing market remains substantial. Active compound concentrations in commercial products are frequently unverified, batch consistency is inconsistent across manufacturers, and the regulatory oversight applied to dietary supplements is materially weaker than that governing pharmaceutical products.

The evidence-informed position is this: the individual ingredients proposed in Purecybin Energy Microdose 150mg have meaningful research support at appropriate doses. Whether a specific commercial product delivers those ingredients at relevant concentrations, with verified purity, and in compliance with applicable law depends entirely on quality assurance standards that must be verified independently by the consumer.

For buyers considering Purecybin Energy Microdose 150mg, the decision framework is straightforward: obtain and evaluate the Certificate of Analysis, confirm GMP manufacturing status, verify legal compliance in your jurisdiction, consult a healthcare provider if you take any serotonergic medications, and apply the verification checklist provided in this guide before any purchase.

The growing interest in natural cognitive enhancers without jitters is legitimate and increasingly well-supported by emerging research. Exercising rigorous due diligence in selecting among commercial products is what separates informed wellness decisions from marketing-driven ones.

Sources and Further Reading

• Carhart-Harris, R. et al. (2021). Trial of psilocybin versus escitalopram for depression. Nature Medicine, 27, 281–289.
• Geng, J. et al. (2010). Ginseng for cognition. Cochrane Database of Systematic Reviews.
• Chen, S. et al. (2010). Cordyceps sinensis and exercise performance. Journal of Alternative and Complementary Medicine, 16(5), 585–590.
• Fadiman, J. (2011). The Psychedelic Explorer’s Guide. Park Street Press.
• Szigeti, B. et al. (2021). Self-blinding citizen science to investigate microdosing psychedelics. eLife, 10, e62878.
• National Institutes of Health. Office of Dietary Supplements — Vitamin B12 Fact Sheet. nih.gov/ods
• Johns Hopkins Center for Psychedelic and Consciousness Research. hopkinspsychedelic.org
• Imperial College London Centre for Psychedelic Research. imperial.ac.uk/psychedelic-research-centre